Is Methamphetamine-Linked Cardiomyopathy an Emerging Epidemic for New Generation?
Copyright © 2021 Elsevier Inc. All rights reserved..
The use of methamphetamines is growing worldwide with cardiovascular disease as the leading cause of mortality and morbidity. Long-term use of methamphetamines is associated with malignant hypertension, myocardial ischemia, pulmonary hypertension, and methamphetamines-associated cardiomyopathy. These effects are noted to be dose-dependent and potentially reversible with discontinuation of methamphetamines in the early stages when there is limited or no myocardial fibrosis. This review aims to (1) summarize the available data from epidemiologic studies, (2) describe pathophysiological mechanisms and clinical presentation, (3) Management of methamphetamines induced cardiomyopathy and potential complications associated with it, and (4) Strategies to reduce methamphetamines abuse and related hospitalization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:48 |
|---|---|
| Enthalten in: |
Current problems in cardiology - 48(2023), 1 vom: 01. Jan., Seite 101042 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Latif, Azka [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 23.11.2022 Date Revised 23.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cpcardiol.2021.101042 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33318615X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33318615X | ||
| 003 | DE-627 | ||
| 005 | 20231225221130.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cpcardiol.2021.101042 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1110.xml |
| 035 | |a (DE-627)NLM33318615X | ||
| 035 | |a (NLM)34780869 | ||
| 035 | |a (PII)S0146-2806(21)00251-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Latif, Azka |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is Methamphetamine-Linked Cardiomyopathy an Emerging Epidemic for New Generation? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.11.2022 | ||
| 500 | |a Date Revised 23.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Inc. All rights reserved. | ||
| 520 | |a The use of methamphetamines is growing worldwide with cardiovascular disease as the leading cause of mortality and morbidity. Long-term use of methamphetamines is associated with malignant hypertension, myocardial ischemia, pulmonary hypertension, and methamphetamines-associated cardiomyopathy. These effects are noted to be dose-dependent and potentially reversible with discontinuation of methamphetamines in the early stages when there is limited or no myocardial fibrosis. This review aims to (1) summarize the available data from epidemiologic studies, (2) describe pathophysiological mechanisms and clinical presentation, (3) Management of methamphetamines induced cardiomyopathy and potential complications associated with it, and (4) Strategies to reduce methamphetamines abuse and related hospitalization | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Methamphetamine |2 NLM | |
| 650 | 7 | |a 44RAL3456C |2 NLM | |
| 700 | 1 | |a Ahsan, Muhammad Junaid |e verfasserin |4 aut | |
| 700 | 1 | |a Lateef, Noman |e verfasserin |4 aut | |
| 700 | 1 | |a Kapoor, Vikas |e verfasserin |4 aut | |
| 700 | 1 | |a Lundgren, Scott |e verfasserin |4 aut | |
| 700 | 1 | |a Ahsan, Muhammad Zoraiz |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Soban |e verfasserin |4 aut | |
| 700 | 1 | |a Mirza, Mohsin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current problems in cardiology |d 1993 |g 48(2023), 1 vom: 01. Jan., Seite 101042 |w (DE-627)NLM000219622 |x 1535-6280 |7 nnns |
| 773 | 1 | 8 | |g volume:48 |g year:2023 |g number:1 |g day:01 |g month:01 |g pages:101042 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cpcardiol.2021.101042 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 48 |j 2023 |e 1 |b 01 |c 01 |h 101042 | ||